Navigation Links
BioElectronics' ActiPatch Reduces Muscle Soreness in Runners
Date:5/7/2012

FREDERICK, Md., May 7, 2012 /PRNewswire/ -- BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, today announced the completion of a randomized, controlled trial on delayed muscle onset soreness using BIEL's ActiPatch® product.  ActiPatch uses pulsed electromagnetic field therapy to reduce pain, inflammation, and promote the healing of injured tissue.

A double blind, randomized, placebo controlled trial on delayed onset muscle soreness after marathon running found that ActiPatch® significantly reduces muscle soreness in the thighs in  runners, in the days after the completion of a marathon, compared to runners who used a placebo device. There was also a strong trend to increased running activity post marathon, which was significant on the first day after the marathon. This research study is now under peer review for publication, and the results will also be presented at EFORT (European Federation of National Associations of Orthopaedics and Traumatology) conference in Berlin, May 2012. The principle investigator leading the research was Dr. Rasmussen, Associate Professor Director of Research, Aarhus University Hospital, Aalborg Hospital, Denmark.

This study also confirms the results in the previous US muscle onset soreness study wherein ActiPatch® showed superior, and statistically significant pain relief compared to the OTC drug, acetaminophen. It has been forwarded to the FDA to support the Company's ActiPatch® application for relief of musculoskeletal pain. 

"We are delighted about the completion of this second randomized control trial on delayed muscle onset soreness," said Ian Rawe, Ph.D., BioElectronics Director of Clinical Research. "There are currently no interventions that can effectively alleviate muscle soreness, and certainly none that allow for quicker return to physical activity. These results suggest that BioElectronics' ActiPatch® device has the potential to be widely used in sports applications, not just for injury recovery but also injury prevention and improved performance. The exposure of these results and our technology at the EFORT conference, presented by a respected researcher, will be extremely beneficial, and in due course will attract more research in this interesting field."

"The fact that these research initiatives have been independently undertaken show that our technology is becoming widely accepted by the medical community," said Andrew Whelan, CEO.

About BioElectronics Corporation

BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:  E & E Communications
Paul Knopick
(949) 707-5365


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Announces Major Clinical Trials
2. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
3. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
4. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
5. BioElectronics Corporation to Webcast, Live, at RetailInvestorConferences.com on October 6th
6. BioElectronics Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
9. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
10. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
11. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Alzheimer Diagnostic Tests - Medical ... Medical Devices sector report , "Alzheimer Diagnostic Tests ... overview of Alzheimer Diagnostic Tests currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Aesthetic Devices ... GlobalData,s Medical Devices sector report, "Aesthetic Devices - Medical ... Devices currently in pipeline stage. This ... secondary and primary research by GlobalData,s team of industry ... be removed or altered based on the availability and ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance ... beginning of a new charity campaign. As part of their ongoing community involvement ... In the belief that children deserve a voice, and in the spirit of ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... frequently. While a significant number of women and men with eating disorders report ... itself, that best predicts the development of an eating disorder. , At ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of Home ... and the Home Health and Hospice ICD-10 Transition Workgroup are working closely with ... guidance and clarifications, to address concerns over the use of 'A' as the ...
Breaking Medicine News(10 mins):